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Children with acute lymphoblastic leukaemia (ALL) with no
adverse risk factors now have more than a 70% chance of survival
(Chessells et al, 1995). As ALL is the most common form of
malignant disease found in children, the numbers of these
survivors reaching adulthood are significant and hence the long-
term complications of their treatment, which include
chemotherapy and radiotherapy, become increasingly important.
We have recently shown that a significant proportion of adults
treated with cranial irradiation (XRT) in childhood as part of their
treatment for ALL, are severely growth hormone (GH)-deficient
and a further proportion are GH-insufficient as a result of radia-
tion-induced hypothalamic damage (Brennan et al, 1998). GH-
deficient adults have a reduction in bone mineral density (BMD)
irrespective of whether the onset of the GH deficiency is in child-
hood (O’Halloran et al, 1993) or adulthood (Holmes et al, 1994b).
Reduction in BMD in children treated for ALL has been
documented (Gilsanz et al, 1990; Halton et al, 1996) however, the
precise interpretation of these findings in a growing skeleton is
difficult unless volumetric measurements of bone mass are
performed.
Little is known about bone mass in adults treated for ALL in
childhood but there is a suggestion that it is reduced and that GH
deficiency appears to be a major factor (Nussey et al, 1994) Thus
in order to explore the effect of GH status on BMD in adult
survivors of childhood ALL in more detail, we have examined the
relationship between BMD, and GH status in 31 adults treated for
childhood ALL compared with a group of age- and body mass
index (BMI)-matched young adults.
MATERIAL AND METHODS
Patients
Thirty-one adults (16 male) were assessed 6.8–28.6 years (median
17.8 years) after cranial irradiation was administered as part of
their treatment for ALL. The median age at diagnosis of ALL was
6.9 years (range 1.7–16 years) and at the time of assessment their
median age was 23 years (range 18.8–33 years). They had
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Summary Bone mineral density (BMD), serum osteocalcin and type I collagen C-telopeptide (ICTP) were assessed in a cohort of 31
(16 males) adults who had received cranial irradiation in childhood as part of their treatment for acute lymphoblastic leukaemia (ALL). Markers
of bone turnover were compared with those of 35 age and body mass index (BMI) matched young adults (18 male). Growth hormone status
had previously been determined using an insulin tolerance test and arginine stimulation test. Eight patients were classified as severe growth
hormone deficiency (group 1), 12 patients as growth hormone insufficient (group 2) and 11 patients as normal (group 3). Vertebral trabecular
BMD, lumbar spine and femoral neck integral BMD and forearm cortical bone mineral content (BMC) was measured 17.8 (6.8–28.6) years
after cranial irradiation and was expressed as Z (standard deviation) scores. There was a significant reduction in vertebral trabecular BMD
(median Z score –1.25, P < 0.001), in lumbar spine integral BMD (median Z score –0.74, P = 0.001), in forearm cortical BMC (median Z score
–1.35, P < 0.001), and less so in femoral neck integral BMD (median Z score –0.43, P = 0.03). There was no difference among the growth
hormone status groups for the following BMD measurements: vertebral trabecular BMD, lumbar spine integral BMD or femoral neck integral
BMD (P = 0.8, P = 0.96 and P = 0.4 respectively). There was only a marginal significant difference for BMD at the wrist between growth
hormone status groups (P = 0.04). There was no correlation between the BMD measurements with time since or age at diagnosis and no
difference in markers of bone turnover between patients and controls; median serum osteocalcin 13.3 and 12.0 ng ml (P = 0.7), respectively,
and for ICTP 5.0 and 4.9 mg L (P = 0.67) respectively. In conclusion, there is a highly significant reduction in BMD in young adults following
treatment for ALL in childhood. The reduction in BMD affects both trabecular and cortical bone but did not seem to be related to time since
diagnosis, age at diagnosis, or current growth hormone status. Possible explanations include a direct effect of chemotherapy, steroids or both
on bone during childhood and hence an effect on the accretion of bone mass. In view of the risk of fractures in patients with osteopenia, adults
treated for ALL in childhood may be at an increased risk of bone fractures later in life irrespective of the underlying cause of the osteopenia
and thus intervention should be considered.
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this had been completed at least 2 years previously in all cases.
They were in first remission, none had received any hormone
replacement therapy, they had all achieved final height and
progressed through puberty spontaneously. All patients at assess-
ment had either normal oestradiol or testosterone levels and
gonadotrophins were within the normal range. No patient had a
history of fractures. A review of all patients’ notes was performed
to obtain details of their chemotherapy and radiotherapy. At
assessment, height was measured and converted to standard devia-
tion (s.d.) scores using the standards of Tanner et al al, (1965a,
1965b). The study was approved by the local Ethics Committee
in Manchester.
Treatment
Treatment for ALL was carried out at one oncology centre, Royal
Manchester Children’s Hospital, over 2–3 years with either
UKALL protocols I, II, III, IV, V, VI, VII, VIII, X or Memphis V.
UKALL protocols I, II, III, V and VII, were standard regimens
consisting of vincristine, prednisolone (total dose 5–5.9 gm m2),
L-asparaginase, methotrexate (total dose 1.7–1.92 gm m2) and
6-mercaptopurine. UKALL IV, VI and Memphis V contained the
same drugs but these were administered in a pulsed manner.
UKALL VIII again included the same drugs but these were admin-
istered in a sustained manner and UKALL X was similar to the
standard regimes but with the addition of intensification blocks in
some, but not all, patients. They had all received between 18 and
25 Gy cranial XRT (11 received 18 Gy) and four of the subjects
had also received 24 Gy spinal irradiation.
Controls
The controls consisted of 35 healthy medical students (18 male).
Their median age (range) was 21.6 (21–25) years. None had
received any chronic medication within the last 3 years and
all underwent a physical examination to exclude any previously
undetected pathology. Only osteocalcin and type I collagen cross-
linked C-telepeptide assay were measured in the controls.
Growth hormone status
Each subject underwent assessment of growth hormone status
using two provocative agents administered individually on two
different mornings. The agents used were intravenous (i.v.) soluble
insulin (Actrapid) 0.2 IU kg body weight and 20 gm m2 of i.v.
arginine (over 30 min). An i.v. canula was inserted after an
overnight fast. Blood samples were taken at time 0 min and then
every 30 min for a total of 180 min. The provocative agent was
administered at time 0 min. Serum GH was measured in each
sample and blood glucose was measured throughout the insulin
tolerance test (ITT). All subjects achieved a blood glucose of less
than 2.0 mmol l during the ITT. The patient cohort was classified
into three GH status groups: (group 1 – GH-deficient, peak GH
response to both tests of less than 9 mU ml; group 2–GH insuffi-
cient, peak GH response to both tests less than 20 mU ml but one
or both responses greater than 9 mU ml; group 3–GH normal, peak
GH response to one or both tests greater than 20 mU ml (Brennan
et al, 1998).
Assays
Serum growth hormone
Serum GH levels were measur
d by two-site immunoradiometric assay. The reference preparation
used was NIBSC 80/505 and the limit of sensitivity of the growth
hormone assay was 1 mU l. The inter-assay coefficients of varia-
tion (CV) for the assay were 8.8, 5.5 and 6.5% for mean GH
results of 9, 25 and 65 mU l.
Osteocalcin
Serum osteocalcin was measured after an overnight fast, using a
two-site immunoradiometric assay (DSL, Webster, TX, USA). All
the samples were assayed in a single batch. The sensitivity of this
assay was 0.27 ng mL. The intra-assay variability was 4.6%, 2.9%
and 1.4% at 2.88, 9.84 and 28.2 ng mL respectively.
Type I collagen cross-linked C-telopetide (ICTP) assay
Serum IcTP was measured using a radioimmunoassay (RIA)
(Telepeptide ICTP, Orion Diagnostica). The sensitivity of this
assay was 0.5 mg l. The intra- and inter-assay CV was 6.2% and
8% respectively
Bone densitometry
Bone mineral density was estimated in the patients only.
Measurements were performed at multiple sites using several
techniques.
Quantitative computed tomography (QCT)
Measurement of vertebral trabecular BMD at T12 to L3 was
performed using single energy QCT on a GE 9800 general purpose
scanner (General Electric, Milwaukee, WI, USA) using a low-
dose scanning technique and a liquid dipotassium hydrogen phos-
phate (K2HPO4) calibration phantom (Cann and Gerant, 1980). In
28 patients QCT was performed using a Philips SR 4000 CT
scanner (Philips Medical Systems, Nederlands BV) and a solid
calcium hydroxyapatite reference phantom (Image Analysys Inc.,
Irvine, CA, USA). Mean trabecular BMD was measured in mg cc
of mineral equivalents of either K2HPO4 in water (n = 4) or
calcium hydroxyapatite (n = 28). Precision (CV%) of the tech-
nique in our department is 1% in normal subjects and 2.5% in
osteoporotic patients (Adams and Adams, 1988; Whitehouse et al,
1990).
Dual energy X-ray absorptiometry (DXA)
Measurement of integral (mixed cortical and trabecular) bone was
made in the lumbar spine (L2 to L4) and the right femoral neck
using a Lunar DPX-L scanner (Lunar Corporation, Madison, WI,
USA) (Callum et al, 1989). Mean BMD was measured in g cm–2.
Precision of the measurement in our department is 0.5% in the
spine and 2.5% in the femoral neck.
Single X-ray absorptiometry (SXA)
Bone density measurement was performed by SXA in the non-
dominant forearm using an Osteometer DTX-100 scanner
(Roedovre, Denmark). Scanning was performed at the distal site,
giving a measurement predominantly of cortical bone. The BMD
was measured in g cm2. The precision of BMD measurement by
SXA is 1%.
To assess whether the measurements made in each individual
were normal or reduced, the values were expressed as Z (s.d.)
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ence data matched for age and sex (Parfitt, 1990). Reference
ranges for QCT were drawn from the normative database of the
University of California, San Francisco. For QCT vertebral trabec-
ular bone measured on the GE scanner the data published by Block
et al, (1989) were used for women and those of Genant et al,
(1983) were used for men. For QCT performed on the Philips CT
scanner reference ranges provided by Image Analysis Inc. (Irvine,
CA, USA) were used (Faulkner et al, 1993). For DXA measure-
ments the reference ranges provided by the manufacturer (Lunar
Corporation, software version 1.3) were used and which have been
found to be appropriate for the local population. The Z scores for
DXA were weight corrected. Similarly, for SXA the manufac-
turer’s reference data was used (Thomsen et al, 1986).
Statistical analysis
Statistical analysis was performed using non-parametric tests.
Comparisons with age- and sex-matched reference data (results
expressed as Z scores) were performed using the Wilcoxon
matched-pairs signed rank test. Comparisons of Z scores between
the GH status groups of patients were performed using the
Kruskal–Wallis test. Comparison between BMD measurements at
different sites, and BMD with time since diagnosis or age at diag-
nosis, are expressed as Spearman’s correlation coefficients (r).
Comparisons of the markers of bone turnover, osteocalcin and
ICTP between patients and controls were performed using the
Mann–Whitney U-test. A P-value of less than 0.05 is considered
statistically significant. Statistical analyses apply to all 31 patients
except for BMD measurements of the spine when patients who had
received spinal irradiation (n = 4) were excluded.
RESULTS
There was a highly significant reduction in vertebral trabecular
BMD (QCT: median Z score –1.25, range –3.51 to 0.95,
P < 0.001), in integral bone of the lumbar spine (DXA: median
Z score –0.74, range –2.1 to 1.00, P = 0.001), in cortical bone of
the forearm (SXA: median Z score –1.35, range –3.4 to 1.8,
P < 0.001), and less so in integral bone of the femoral neck (DXA:
median Z score –0.43, range –1.4 to 1.65, P = 0.03) [Figure 1].
Height at assessment was analysed only in the 28 subjects who
had received cranial irradiation alone (n = 28). The final height
SDS was significantly different from zero (median –0.7, range
–3.6 to 0.9, P < 0.001).
In terms of GH status, eight patients were classified as severe
GH-deficient (group 1), 12 patients GH insufficient (group 2) and
11 patients normal (group 3). Bone mineral density data catego-
rized in terms of GH status are summarized in Table 1. There was
no difference amongst the GH status groups for the following
BMD measurements, QCT spine, DXA spine or DXA femoral
neck (P = 0.8, P = 0.96 and P = 0.4 respectively). There was only
a marginal significant difference for BMD at the wrist between the
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Figure 1 Bone mineral density Z scores of patients. Horizonal bars
represent median values; QCT (–1.25), DXA spine (–0.74), DXA femoral
neck (–0.43) and SXA (–1.35)
Table 1 Bone mineral density for patients expressed as Z scores in GH status groups. (Severe GHD [1], GH insufficient [2] and normal
[3]); data expressed as median (range)
Group 1 Group 2 Group 3
QCT –1.26 (–2.3–0.8) –1.1 (–3.5–0.1) –1.26 (–3.1–0.95)
DXA spine –0.5 (–2.1–1) –0.75  (–1.6–0.7) –0.76  (–1.8–0.2)
DXA femoral neck –0.61 (–1.4–0.3) –0.14 (–1.3–1.1) –0.43  (–1.1–1.65)
SXA –1.1 (–3.4–0.2) –2 (–2.9–0.1) –1.1 (–1.9–1.8)
Table 2 Correlations between bone mineral density measurements at different sites, and time since or age at diagnosis
Age at diagnosis Time since diagnosis SXA QCT DXA spine
SXA r = 0.11 r = 0.07
P = 0.57 P = 0.7
QCT r = –0.2 r = 0.25 r = 0.07
P = 0.93 P = 0.2 P = 0.73
DXA spine r = –0.17 r = 0.19 r = 0.45 r = 0.33
P = 0.38 P = 0.33 P = 0.02 P = 0.08
DXA femoral neck r = 0.09 r = 0.15 r = 0.14 r = 0.53 r = 0.41
P = 0.62 P = 0.42 P = 0.45 P = 0.004 P = 0.03GH status groups (P = 0.04) but the lowest median Z score was in
GH status group 2 (median Z score –2) and not the severely
GH-deficient group (median Z score – 1.1).
There was no correlation between the BMD measurements at
any of the four sites, DXA spine, DXA femoral neck, SXA wrist
and QCT spine, with time since or age at diagnosis (Table 2).
There were significant correlations between DXA spine with DXA
femoral neck and SXA, and also between DXA femoral neck and
QCT spine (Table 2).
There was no difference in markers of bone turnover between
patients and controls; median (range) serum osteocalcin 13.3
(1.8–40.7) and 12.0 (2.9–43.6) ng ml (P = 0.7), respectively,
and for ICTP 5.0 (2.7–8.8) and 4.9 (3.5–8.3) mg  L (P = 0.67)
respectively.
DISCUSSION
Height and body size are known to correlate with BMD (Prentice
et al, 1994), therefore, we have considered the possibility that the
short stature of our patients might be responsible for falsely low
BMD estimations. DXA and SA provide areal measurement of
BMD and could give falsely low BMD estimations in short
subjects. The use of QCT to measure spinal BMD, however,
avoids the influence of height on BMD measurement as it is a
volumetric measurement of BMD in g cm3. Furthermore, although
the final height standard deviation score (SDS) of the whole cohort
of patients was significantly reduced (Brennan et al, 1998), the
reduction in stature was only noted in a subset of the patients,
i.e. severely GH-deficient (group 1), but not in GH status groups
2 or 3. Nonetheless, there was no difference in BMD measure-
ments between the three GH status groups. We conclude that the
highly significant decrease in BMD in our patient cohort reflects a
significant reduction in bone mass rather than mis-interpretation
due to the limitations imposed by certain radiological techniques.
Bone mineral density in children treated for ALL has been
investigated before final height has been achieved (Gilsanz et al,
1990; Halton et al, 1996). Gilsanz et al, (1990) examined BMD in
42 children (mean age 11.77 ± 0.53 years) following treatment for
ALL using QCT of the spine. The survivors of childhood ALL had
lower trabecular bone density in the spine compared with the
controls; however, the overall results were heavily influenced by a
subgroup of ALL survivors who had received cranial irradiation.
Therefore Gilsanz et al (1990) suggested that GH deficiency was a
possible cause of the reduction in BMD. Gilsanz et al (1990) also
observed no relationship between reduction in BMD and age at
time of diagnosis or time since completion of therapy.
Growth hormone deficiency whether of childhood (Kaufman
et al, 1992; O’Halloran et al, 1993; De Boer et al, 1994), or adult
onset, (Rosen et al, 1993 Holmes et al, 1994b) results in a signifi-
cant reduction in BMD. In adults with childhood onset GH
deficiency osteopenia is more severe than adult onset GH defi-
ciency (Holmes et al, 1994b), and is likely to be due to failure of
accretion of bone mass rather than accelerated bone loss (Kaufman
et al, 1992). Growth hormone status in our patients, however, did
not seem to influence the reduction in BMD in that patients with
severe GH deficiency (group 1), who despite having the greatest
loss in height SDS (–2.1) consistent with the presence of GH
deficiency for some time (Brennan et al, 1998) did not have the
greatest reduction in BMD Z score. This is in contrast to a
previous study where GH deficiency appears to be a major factor
in the osteopenia seen in a similar cohort of adults survivors of
childhood leukaemia (Nussey et al, 1994). The definition of GH
deficiency in this latter cohort of patients was, however, less
rigorous as it was determined clinically in most patients. GH
responses to provocative stimuli were determined in only a
minority of patients. Furthermore, their analysis was complicated
by including spinal BMD data from patients who had received
spinal irradiation a known independent cause of osteopenia
(Nussey et al, 1994).
Apart from GH deficiency, there are other possible hormonal
influences on BMD. It is well established that hypogonadism in
either sex is associated with a reduction in BMD (Stepan et al,
1989; Kreuser et al, 1992; Holmes et al, 1994a). However, all
patients in this study had progressed through puberty sponta-
neously and were of normal sex steroid status during adult life
when their GH status and BMD were assessed.
Glucocorticoid treatment can cause osteopenia (Baylink, 1983),
and as all our patients would have received between 2 and 3 years
of prednisolone therapy with a 5-day course every 4 weeks, this
must be considered as a possible cause of the osteopenia. Patients
with glucocorticoid-induced osteoporosis lose more trabecular
than cortical bone; consequently, they have greater bone mineral
loss in the vertebrae (Lukert and Raisz, 1990; Reid and Grey,
1993). Furthermore, the predominant result of glucocorticoid
treatment is an impairment of bone formation with a decrease in
serum osteocalcin, a marker of osteoblastic function (Peretz et al,
1989). In our patient cohort there was a significant reduction
in both trabecular and cortical bone with a greater, but not signifi-
cant, reduction in cortical bone at the wrist. There was no differ-
ence between patients and controls in markers of bone turnover, in
particular no difference in serum osteocalcin levels.
An alternative aetiology for the osteopenia is cytotoxic
chemotherapy. Short-term treatment of rats with methotrexate and
doxorubicin has been shown to cause a significant reduction in
vertebral trabecular bone volume and in bone formation rate
(Friedlaender et al, 1984) raising the possibility that chemotherapy
agents may have a direct effect on bone turnover, and hence BMD,
in man. Methotrexate is also a key component of the ALL drug
treatment received by children at least weekly during the 2 or 3
years of treatment. In childhood ALL treatment regimes where
higher doses of prednisolone and methotrexate are used, such as
Dana Fabar regime, significant reduction in BMD is seen during
therapy (Halton et al, 1996).
In conclusion, we have shown a significant reduction in BMD in
adult’s treatment for ALL in childhood. In this cohort current GH
status did not seem to influence the reduction in BMD. Possible
explanations include a direct effect of chemotherapy, steroids or
both on bone during childhood and hence an effect on the accre-
tion of bone mass. This requires further study in patients who are
now coming up to adulthood, having been treated for ALL in
childhood. The current regimes in the UK have an increased inten-
sity of chemotherapy but less than 10% of children will receive
cranial irradiation. It is likely that children who have not received
cranial irradiation, have normal GH secretion. The therapeutic
implications may differ for these osteopenic young adults depen-
dent upon the primary modalities of therapy that they have been
exposed to.
In view of the risk of fractures in patients with osteopenia
(Cummings et al, 1993), adults treated for ALL in childhood may
be at an increased risk of bone fractures later in life irrespective of
the underlying cause of the osteopenia and thus intervention
should be considered. If adults treated for ALL in childhood are
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reason for GH replacement irrespective of whether or not the
osteopenia is due to GH deficiency. In other words the osteopenia
of GH deficiency will be superimposed on osteopenia of other
causes if left untreated. In those patients osteopenic but not
GH-deficient or GH-deficient but unresponsive to GH replace-
ment, drugs which inhibit bone resorption should be considered.
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